- Conditions
- Hereditary Angioedema
- Interventions
- C1 Esterase Inhibitor
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 13
- States / cities
- Weston, Florida • Atlanta, Georgia • Idaho Falls, Idaho + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- C1 esterase inhibitor [human] liquid, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 13 more
- Conditions
- Angioedema
- Interventions
- Icatibant, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • San Diego, California + 5 more
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, Hereditary Angioedema - Type 3, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema Type III, Hereditary Angioedema (HAE), Hereditary Angioedema Type I and II, HAE With Normal C1 Esterase Inhibitor
- Interventions
- deucrictibant
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 9 more
- Conditions
- Hereditary Angioedema, HAE
- Interventions
- Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
- Genetic
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
- Conditions
- Hereditary Angioedema
- Interventions
- CINRYZE with rHuPH20
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 1 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CINRYZE
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 8
- States / cities
- Colorado Springs, Colorado • Tampa, Florida • Chevy Chase, Maryland + 5 more
- Conditions
- Hereditary Angioedema
- Interventions
- C1 inhibitor (human) [C1 INH]
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Wheaton, Maryland + 8 more
- Conditions
- Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- San Diego, California • Walnut Creek, California • St Louis, Missouri + 1 more
- Conditions
- Hereditary Angioedema
- Interventions
- CINRYZE
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 4 more
- Conditions
- Hereditary Angioedema
- Interventions
- rhC1INH
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 2 Years to 13 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Hereditary Angioedema Types I and II
- Interventions
- C1-esterase inhibitor - single intravenous dose, C1-esterase inhibitor - subcutaneous low dose, C1-esterase inhibitor - subcutaneous medium dose, C1-esterase inhibitor - subcutaneous high dose
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chevy Chase, Maryland • Cincinnati, Ohio + 2 more
- Conditions
- Hereditary Angioedema (HAE), Angioedema, Bradykinin-mediated Angioedema, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule, Placebo comparator to 20 mg capsule
- Drug
- Lead sponsor
- Institute for Asthma and Allergy
- Network
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Wheaton, Maryland
- Conditions
- Hereditary Angioedema (HAE), Angioedema
- Interventions
- Lanadelumab 150 mg, Lanadelumab 300 mg
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CINRYZE with rHuPH20
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 14 more
- Conditions
- Hereditary Angioedema
- Interventions
- C1 Esterase Inhibitor, Placebo
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 17
- States / cities
- Granada Hills, California • Weston, Florida • Atlanta, Georgia + 14 more
- Conditions
- Hereditary Angioedema
- Interventions
- rhC1INH, Placebo (Saline)
- Drug
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more
- Conditions
- Hereditary Angioedema
- Interventions
- Ruconest
- Biological
- Lead sponsor
- Bernstein Clinical Research Center
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Cincinnati, Ohio
- Conditions
- Acute Hereditary Angio Edema
- Interventions
- OCTA-C1-INH, Placebo
- Drug · Other
- Lead sponsor
- Octapharma
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
- Interventions
- Deucrictibant low dose, Deucrictibant high dose, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
- Conditions
- Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor [C1-INH] Deficiency, C1 Esterase Inhibitor Deficiency, C1 Esterase Inhibitor, Deficiency of, C1 Inhibitor Deficiency, Hereditary Angioedema - Type 3, Hereditary Angioedema Type III
- Interventions
- Deucrictibant, Placebo
- Drug
- Lead sponsor
- Pharvaris Netherlands B.V.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Paradise Valley, Arizona • Little Rock, Arkansas + 10 more
- Conditions
- Hereditary Angioedema (HAE)
- Interventions
- CINRYZE 500, CINRYZE 1000
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 3
- States / cities
- Colorado Springs, Colorado • Las Vegas, Nevada • Eugene, Oregon
- Conditions
- Hereditary Angioedema
- Interventions
- Recombinant human C1 inhibitor, Placebo
- Biological · Other
- Lead sponsor
- Pharming Technologies B.V.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 4
- States / cities
- Tampa, Florida • St Louis, Missouri • Lake Oswego, Oregon